Search

The synthesis of nucleotides in the body is centrally controlled by the liver, via salvage or de novo synthesis. We reveal a pervasive circadian influence on hepatic nucleotide metabolism, from rhythmic gene expression of rate-limiting enzymes to oscillating nucleotide metabolome in wild-type (WT) mice. Genetic disruption of the hepatic clock leads to aberrant expression of these enzymes, together with anomalous nucleotide rhythms, such as constant low levels of ATP with an excess in uric acid, the degradation product of purines. These results clearly demonstrate that the hepatic circadian clock orchestrates nucleotide synthesis and degradation. This circadian metabolome timetable, obtained using state-of-the-art capillary electrophoresis time-of-flight mass spectrometry, will guide further investigations in nucleotide metabolism-related disorders., (Copyright © 2012 The Authors. Published by Elsevier Inc. All rights reserved.)

Cyclic adenosine monophosphate (cAMP) was found to decrease the availability of 5-phosphoribosyl-1-pyrophosphate (PRPP) and to decelerate the rate of de novo purine synthesis in suspensions of adult rat hepatocytes. Glucagon did not affect these parameters. The glucagon antagonist des-His1[Glu9]glucagon amide (DHGA), and the protein kinase C activator 1,2-dioctanoyl-sn-glycerol (DOG) were also found to lower PRPP availability. Incubation of the hepatocytes with dbcAMP or with DHGA, did not alter the activity of PRPP synthetase in the hepatocyte lysates, indicating that the above effects are not mediated through the activity of this enzyme. The possibility that the decrease in PRPP availability reflects increased consumption associated with accelerated pyrimidine synthesis is discussed. The decelerated rate of de novo purine synthesis is probably secondary to the decreased PRPP availability.

The effect of insulin on the rate of de novo purine biosynthesis was studied in freshly isolated hepatocytes from adult male rats. Insulin started to increase the rate of de novo purine biosynthesis at 1.5 X 10(-10) M and plateaued at 1.5 X 10(-8) M with the magnitude of increase of about 280%. Insulin at 1.5 X 10(-9) M or the higher concentration increased the 5-phosphoribosyl 1-pyrophosphate (PRPP) availability for purine ribonucleotide synthesis to about 230%. Insulin increased ATP concentration to 127% and decreased AMP, ADP, GMP and GDP concentration to 73, 69, 73 and 69% in association with the increased adenylate energy charge of 0.90 in comparison to the control level of 0.83. But the total adenine and guanine nucleotide concentration in the cell was not significantly changed. In addition insulin increased the specific activity of amidophosphoribosyltransferase (ATase) with the increased Vmax and the unchanged Km for PRPP.

Incubation of freshly isolated rat liver cells with glycerol resulted in an initial decrease, followed by an increase in purine synthesis de novo and in PP-ribose-P availability. The magnitude of these effects was dependent on the concentration of glycerol; as it increased, the initial period of latency or inhibition was prolonged, and the extent of the subsequent stimulation was greater. The intracellular Pi concentration and the [14C]ATP/[14C]ADP ratio were also initially decreased in these cells, and they too returned subsequently to normal values. All these changes were similar to those induced by fructose under the same conditions. The increase in PP-ribose-P availability always preceded that in purine synthesis de novo, indicating that, under most circumstances, PP-ribose-P availability is limiting for purine synthesis de novo. Finally, PP-ribose-P synthesis in these cells varied in parallel with the intracellular Pi concentration and with the ATP/ADP and ATP/AMP ratios.

Although folic acid is known to be involved in the pathways of purine metabolism, the precise changes brought about in purine synthesis, reutilization, pool sizes, and ratios by experimental folate deficiency are not clear. Consequently, these aspects of purine metabolism were measured in hepatocytes from control and folate-deficient rats fed an amino acid diet with and without folic acid, respectively. Purine synthesis and reutilization were measured as the rates of incorporation of [U-14C]glycine and [G-3H]hypoxanthine, respectively, into the adenine and guanine pools of freshly isolated hepatocytes after a 3-hour incubation in folate-free, as well as folate- and/or thymidine-supplemented culture media. Hepatocytes from folate-deficient rats had the same rates of purine synthesis as those from control rats. Purine reutilization, purine pool sizes, and the adenine:guanine ratios were lower in hepatocytes from deficient compared with control rats. Purine synthesis was increased when folic acid or thymidine was added to the culture medium. Although hepatocytes from folate-deficient rats had a lower rate of purine reutilization compared with those from control rats, the reutilization rates did not respond to the addition of folic acid or thymidine to the culture medium. The data suggest that purine synthesis was not impaired but purine reutilization was diminished in folate deficiency. Thymidine was as effective as folic acid in stimulating purine synthesis in both control and folate-deficient hepatocytes.

Purine synthesis de novo and its regulation were studied in freshly isolated hepatocytes from fed adult male rats. The cells incorporated [14C]formate mainly into purine ribonucleotides. The immediate effect of increasing the concentration of inorganic phosphate in the incubation medium was an increase in 5-phosphoribosyl 1-pyrophosphate (PP-ribose-P) availability and a stimulation of purine synthesis de novo. However, prolonged incubation of cells in 25 mM phosphate resulted in a decreased PP-ribose-P availability and purine synthesis de novo. Methylene blue and phenazine methosulfate decreased PP-ribose-P availability and purine synthesis de novo although they stimulated considerably the pentose phosphate pathway. In contrast, epinephrine and glucagon increased significantly PP-ribose-P availability and purine synthesis de novo, but they did not change the activity of the pentose phosphate pathway. These results show a relationship between PP-ribose-P availability and purine synthesis de novo in rat hepatocytes. They emphasize the complexity of the regulation of PP-ribose-P availability.

The enzymes of the de novo purine biosynthetic pathway have been partially co-purified from pigeon liver by a method dependent upon the use of the nonionic polymer polyethylene glycol for enzyme stabilization and cofractionation. Although the enzymes did not appear to constitute a large macromolecular complex it was evident that some particular inter-relationship between them was preserved during the purification procedure. Analysis of the end products and pathway intermediates was carried out primarily by sensitive high pressure liquid chromatographic techniques. Substrate and cofactor requirements were confirmed and optimal conditions of pH, temperature, and K+ ion activation established. At phosphoribosyl pyrophosphate (PP-ribose-P) concentrations below 0.3 mM the activity of the first pathway enzyme amidophosphoribosyltransferase was rate-limiting, and the inhibition of this enzyme by AMP regulated the rate of purine ring synthesis. At higher concentrations of PP-ribose-P, aminoimidazole ribonucleotide synthetase, the fifth enzyme of the pathway became rate limiting and was subject to inhibition by added AMP. It was evident that the regulation of purine synthesis was quite complex and that AMP inhibition (perhaps reflected in a low adenylate energy charge) can be effected at different points on the purine pathway.

The labeling of hepatic purines with [14C]glycine increased in the regenerating rat liver 12 hours after a 70% hepatectomy and it reached the 2.4 folds higher peak 12 hours after the surgical operation in comparison to sham-operated control. These observations suggest that the rate of de novo biosynthesis increases in the regenerating rat liver to supply purine ribonucleotides to the cells. In the regenerating rat liver the activity of amidophosphoribosyltransferase (ATase) significantly increased and reached the 1.8 folds higher peak than control 18 hours after surgery. Hepatic 5-phosphoribosyl 1-pyrophosphate (PRPP) concentration significantly increased and reached the 3.0 folds higher peak 12 hours after surgery. Although the mean hepatic concentration of ATP and GTP showed a 13 and 15% decrease respectively in the regenerating rat liver 12 hours after surgery, they were counterbalanced by the increased concentrations of AMP and GMP by 13 and 44% respectively. These results suggest that the increased rate of de novo purine biosynthesis in the regenerating rat liver is mediated by the increased enzymatic activity of ATase and by the increased concentration of PRPP.

Three activities on the pathway of purine biosynthesis de novo in chicken liver, namely, glycinamide ribonucleotide synthetase, glycinamide ribonucleotide transformylase, and aminoimidazole ribonucleotide synthetase, have been found to reside on the same polypeptide chain. Three diverse purification schemes, utilizing three different affinity resins, give rise to the same protein since the final material has identical specific activities for all three enzymatic reactions and a molecular weight on sodium dodecyl sulfate gels of about 110 000. A single antibody preparation precipitates all three activities and binds to the multifunctional protein obtained by two methods in Western blots. Partial chymotryptic digestion of the purified protein gives rise to two fragments, one possessing glycinamide ribonucleotide synthetase activity and the other containing glycinamide ribonucleotide transformylase activity.

2-Ethylamino-1,3,4-thiadiazole (EAT), originally tested as a cancer chemotherapeutic agent, has been shown to increase the de novo synthesis of purines. To evaluate its effects on hepatic adenosine nucleotides in hemorrhagic shock, EAT was administered to dogs prior to bleeding. Concentrations of uric acid and allantoin in serum and lymph were also measured as additional indices of purine metabolism in the dog. During oligemia, the adenosine triphosphate (ATP) in serial liver biopsies fell to half of the control values in treated and untreated groups. After reinfusion, the APT and total adenosine nucleotides increased in both groups but were significantly higher in treated than in untreated control animals (P less than 0.05). In treated animals the hepatic ATP reached 93% and 109% of initial values at one and three hours after reinfusion, respectively. Corresponding values were 63% and 80% in surviving untreated control animals. During oligemia and after reinfusion, the uric acid was increased in both groups but remained significantly lower in treated than in untreated animals. The arterial pressure of treated animals remained higher after reinfusion than in untreated animals. Studies in oligemic rats demonstrated significantly greater survival in EAT-treated animals than in untreated controls. The data suggest that pretreatment with EAT results in improved recovery of the hepatic adenosine nucleotide pool and increased survival of oligemic animals, which may be related to the greater availability of substrates for synthesis of the adenosine nucleotides.

The rate of purine de novo synthesis from sodium formate in developing rat brain falls in the late gestational stages to birth, rises again in the 1st week of life and then decreases rapidly to the 3rd week, and continues declining up to 8 weeks of life (adulthood). The changes in the overall purine biosynthetic rate with respect to time are similar to those in the activity of the rate-limiting enzyme [amidophosphoribosyltransferase (phosphoribosyl diphosphate amidotransferase; EC 2.4.2.14)]. Azaserine [O-diazoacetyl-L-serine], a known inhibitor of glutamine requiring metabolic steps, inhibits purine de novo synthesis by more than 90%. This confirms that the method used to assess purine de novo synthesis in fact does so. The effects of virazole [1-beta-ribofuranosyl-1-H,1,2,4-triazole-3-carboxamide], an inhibitor of IMP dehydrogenase (EC 1.2.1.14), and of alanosine [L-2-amino-3-(hydroxynitrosamino)propanoic acid] an inhibitor of adenylosuccinate synthetase (EC 6.3.4.4), on the rate of purine de novo synthesis were investigated in liver and brain tissue. The effect of the xanthine oxidase inhibitor allopurinol [4-hydroxypyrazolo(3,4-d)pyrimidine] was also investigated in liver tissue. The biosynthesis of the purines which were extruded into the incubation medium as well as those which remained in the tissue was studied. Only inhibitory effects were observed, and these were confined to the purines remaining in the tissue. Allopurinol was completely inert from this viewpoint. The results are compared with those of other workers using lymphoid cells, and emphasize the differences in the control of de novo purine synthesis in different tissues and under different conditions.(ABSTRACT TRUNCATED AT 250 WORDS)

The activity of the two folate dependent enzymes supplying carbon 2 and carbon 8 of the purine nucleus was assayed in the bone marrow of rats and man, as well as in rat livers. The activity of both enzymes was several fold greater in marrow than in liver. Inactivation of cobalamin by exposure to nitrous oxide did not affect the enzymes in rat marrow cells, although an appreciable effect on hepatic enzymes was found. The depression of hepatic glycinamide ribotide (GAR) transformylase in rats exposed to nitrous oxide was prevented by supplying a formate precursor, methylthioadenosine. There was a considerable rise in the activity of GAR transformylase in human marrow cells from patients with megaloblastic anaemia due to cobalamin deficiency but no change in activity in marrow from patients deficient in folate.

In bilaterally adrenalectomized rat liver the increased rate of de novo purine synthesis was shown by the increased [14C]glycine incorporation into hepatic acid-soluble purines with unchanged rapidly miscible glycine pool size and its turnover rate and by the increased rate of chasing of radiolabeled purines. At 24 h after adrenalectomy, the rate of de novo purine synthesis increased by 70%, 5-phosphoribosyl-1-pyrophosphate (PRPP) content increased by 200%, the specific activity of amidophosphoribosyltransferase (EC 2.4.2. 14; ATase) did not change, ATP and GTP showed a 33 and 24% decrease, and AMP and ADP showed a 245 and 38% increase. Combined, the metabolic pool size data reflected an unchanged total inhibitory potential on ATase. Replacement with corticosterone acetate for 24 h partially restored some of these abnormalities. These results suggest that the increase in the rate of de novo purine synthesis in adrenalectomized rat liver is secondary to increased catabolism of purine ribonucleotides and mediated by increased PRPP concentrations.

The incorporation of [14C]glycine to hepatic purines increased proving the increased rate of de novo purine biosynthesis in rat liver after bilateral adrenalectomy in comparison to sham-operated controls. In the liver of adrenalectomized animals 24 hours after adrenalectomy when the rate of de novo purine biosynthesis is increased above control by 70% there was a 200% increase of 5-phosphoribosyl 1-pyrophosphate (PRPP) concentration. The concentrations of purine ribonucleotides showed a 33 and a 24% decrease of ATP and GTP, and 245 and 38% increase of AMP and ADP respectively associated with the unchanged total adenine and guanine nucleotide concentration and a 18% decrease of adenylate energy charge. The specific activity of amidophosphoribosyltransferase (ATase) was not changed. The replacement with corticosterone acetate to adrenalectomized animals for 24 hours partially restored the rate of de novo purine biosynthesis and the concentrations of purine ribonucleotides. These results suggest that the increased rate of de novo purine biosynthesis in adrenalectomized rat liver is compensatory against the increased catabolism of purine ribonucleotides as a result of the increased AMP concentration and that it is mediated by the increased concentration of PRPP. Our study has demonstrated the importance of the physiological amount of adrenocortical hormone to sustain the normal concentrations and the metabolism of purine ribonucleotides in liver.

N2O oxidizes and inactivates cob[I]alamin, and animals exposed in this way serve as models for cobalamin 'deficiency'. Such animals show a fall in activity of glycinamide ribotide transformylase and a rise in that of 5-amino-4-imidazolecarboxamide ribotide transformylase. The fall in glycinamide ribotide transformylase activity was prevented by parenteral 5'-methylthioadenosine derived from methionine. Methylthioadenosine in turn is converted into formate. Activity of glycinamide ribotide transformylase recovers after 7 days despite continued N2O inhalation, and this is probably related to restoration of methionine synthesis by induction of betaine:homocysteine transmethylase.

The effect of malotilate (diisopropyl 1,3-dithiol-2-ylidenemalonate) on de novo purine synthesis was studied in rat liver in vivo and in primary cultured rat hepatocytes in vitro. In the in vivo system, malotilate increased [14C]glycine incorporation by 1.4- to 1.7-fold into acid soluble hepatic purines 4 to 18 hr and the rapidly miscible glycine pool size at least by 2.0-fold 12 hr after administration. Malotilate did not change 5-phosphoribosyl-1-pyrophosphate concentration but increased significantly amidophosphoribosyltransferase (E.C. 2.1.2.14) activity per unit of DNA or per unit of liver protein. Malotilate also increased significantly the hepatic cyclic AMP concentration 2 to 12 hr after administration. In the in vitro system, malotilate increased [14C] formate incorporation into acid soluble purines with accompanying increases in 5-phosphoribosyl-1-pyrophosphate availability and the specific activity of amidophosphoribosyltransferase. These results suggest that malotilate increases the rate of de novo purine synthesis in the liver by its direct action on hepatocytes, the mechanism of this increase is due to the combined increase of amidophosphoribosyltransferase activity and 5-phosphoribosyl-1-pyrophosphate supply and cyclic AMP may play a role for this response.

The differences between the uricotelic chick and the ureotelic rat, in the regulation of purine synthesis de novo, were studied in intact liver tissue. Chick liver, in comparison with rat liver, was found to contain a high activity of purine synthesis de novo, a high content and availability of 5-phosphoribosyl 1-pyrophosphate (PP-rib-P), comparable activity of PP-rib-P synthetase, and low activity of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and of adenine phosphoribosyltransferase (APRT). The results suggest that the intensive activity of the pathway of purine synthesis de novo in the chick liver is mediated by the high PP-rib-P concentration, which may be due at least in part to the relative partial deficiency of HGPRT.

1. Isolated chick lymphoid cells, together with isolated chick liver and kidney cells, incorporate [1-14C]glycine or [14C]formate into urate. 2. Of the cell types used, bursal cells incorporate 14C into urate at the fastest rate, although the output of total urate by bursal cells is only 10% that of liver cells. 3. When suspended in Eagle's medium the incorporation of 14C into urate is inhibited by adenine and guanine up to 1 mM. In contrast, the addition of 1 mM-AMP or -GMP results in a relatively large stimulation of this incorporation. 4. Added adenine is rapidly taken up by liver cells and then released in an unmetabolized form; AMP is taken up more slowly and is rapidly metabolized. The metabolites (possibly including adenine) are then released. 5. Intracellular liver 5-phosphoribosyl 1-pyrophosphate is approx. 0.7mM and remains constant or falls slightly during a 3 h incubation of the cells. 6. The addition of adenine or guanine, AMP or GMP, does not alter liver intracellular 5-phosphoribosyl 1-pyrophosphate concentrations. Added 5-phosphoribosyl 1-pyrophosphate is not taken up by liver cells. 7. The results are discussed in the context of the control of urate and purine synthesis de novo in the chick.

The rates of de novo purine and protein synthesis were assessed in vivo in rat liver after bolus administration of glucagon. The specific activity of hepatic purines and the specific activity ratio of hepatic purine/protein were used as an index of the rate of de novo purine synthesis and the rate relative to protein. Glucagon at doses of 0.01 mg to 0.1 mg/200 g body weight (BW), administered as an intravenous bolus, inhibited dose-dependently the rate of de novo purine synthesis and the rate relative to protein although it increased dose-dependently the hepatic concentration of 5-phosphoribosyl 1-pyrophosphate (PRPP). The inhibition of the rate of de novo purine synthesis recovered to control levels during the period between 60 and 90 minutes after glucagon administration. Dibutyryl cyclic AMP (Bt2 cAMP) partially mimicked this effect of glucagon in that it did not increase the rate of de novo purine synthesis in spite of increased concentrations of PRPP. These results suggest that an intravenous bolus of glucagon inhibits the rate of de novo purine synthesis through increasing cAMP concentration. The data are consistent with inhibition of amidophosphoribosyltransferase (ATase) in spite of increased PRPP concentrations.

In ureotelic species, such as the rat, adaptive changes in metabolic flux and enzyme levels occur in the purine metabolic pathway when cells are rapidly growing. This is observed in both regenerating liver and in malignant tissues. The enzymes P-Rib-PP amidotransferase and IMP dehydrogenase increase in activity in both situations. The level of purine biosynthesis is much higher in uricotelic species, such as the chick, when compared to ureotelic animals. By treating immature roosters with the hormone beta-estradiol, it is possible to induce rapid liver growth, allowing comparison of the regulation of purine biosynthesis and interconversion in high metabolic rate cells with different roles for purine metabolism. The tissue activities of P-Rib-PP amidotransferase, xanthine dehydrogenase, adenylosuccinate synthetase and lyase, AMP deaminase, IMP dehydrogenase, and GMP synthetase did not rise in livers from estradiol-treated chicks, as compared to controls. However, the rate of de novo purine synthesis triples and the intracellular level of P-Rib-PP doubles within 24 h of treatment. The biosynthesis of GMP is elevated at 12 and 24 h, but the levels of soluble nucleotide pools do not change. These data indicate that regulation of the de novo purine pathway in uricotelic species in a high metabolic situation is at the level of substrate availability (P-Rib-PP) and not due to changes in enzyme level or to feedback inhibition.

Based on the parallel increases of glucagon, the second peak of hepatic cAMP, and the rate of purine synthesis de novo in the prereplicative period in regenerating rat liver after a 70% hepatectomy, it was hypothesized that glucagon is responsible for the increased rate of purine synthesis de novo. To test this hypothesis, the effect of glucagon or dibutyryl cAMP infusion on the rate of purine synthesis de novo in rat liver was studied. Glucagon infusion but not insulin or glucose infusion increased the rate of purine synthesis de novo, which was assayed by [14C]glycine or [14C]formate incorporation, by 2.7- to 4.3-fold. Glucagon infusion increased cAMP concentrations by 4.9-fold and 5-phosphoribosyl-1-pyrophosphate concentrations by 1.5-fold in liver but did not change the specific activity of amidophosphoribosyltransferase (EC 2.4.2.14) or purine ribonucleotide concentrations. Dibutyryl cAMP infusion also increased the rate of purine synthesis de novo by 2.2- to 4.0-fold. Because glucagon infusion increased the rate of purine synthesis de novo in the presence of unchanged purine ribonucleotide concentrations, it is concluded that glucagon after infusion or in animals after a 70% hepatectomy is playing an anabolic role to increase the rate of purine synthesis de novo by increasing cAMP and 5-phosphoribosyl-1-pyrophosphate concentrations.